Sotera Health announced today that it has acquired New Jersey-based Gibraltar Laboratories. This acquisition expands the U.S.-based analytical testing capabilities of Sotera Health’s Nelson Labs business. Gibraltar Laboratories is an outsourced provider of microbiology and analytical chemistry testing for pharmaceutical and medical device manufacturers. Terms of the deal were not disclosed.
 
Headquartered in Fairfield, N.J., Gibraltar Laboratories has an outstanding reputation for customer service, technical expertise and quality performance. Gibraltar is known for USP compendial microbiology, sterility assurance, and analytical chemistry testing. The company, owned and operated by the Prince family since 1970, runs two laboratories in the New Jersey tri-state area.
 
“Gibraltar Laboratories is a well-respected laboratory known for its strong customer relationships with U.S.-based pharmaceutical manufacturers,” said Michael B. Petras Jr., CEO of Sotera Health. “In addition to its testing expertise, Gibraltar’s facilities are located in the Northeast pharmaceutical corridor, home to many of the top pharmaceutical manufacturers in the United States. This acquisition will expand our presence in this important region and further strengthen our testing capabilities for the pharmaceutical industry. We welcome Gibraltar’s strong management and expert staff as they join our mission of Safeguarding Global Health.”
 
“Through the commitment of three generations of the Prince family, as well as our experienced staff of microbiology and chemistry professionals, we have earned a reputation as a reliable, responsive and highly professional partner for our customers, and we know we have found the same in Sotera Health,” said Dr. Daniel L. Prince, president of Gibraltar Laboratories. “My goal is for Gibraltar to continue to build on its long-standing reputation of excellence and continue to expand its offerings. We accomplish this by becoming part of Sotera Health, a global company whose breadth of services and expansive reach provide extraordinary value to the industries we are proud to serve.”
 
“Gibraltar’s offerings and the strategic location of its facilities will be a great benefit to our mutual customers, who value working with a trusted partner that can consistently deliver quality, service and expertise,” said Jeff Nelson, president of Nelson Labs. “The Gibraltar team is known for these values and also has an excellent reputation for designing specialized studies that help manufacturers prove the safety, efficacy, and regulatory compliance of their products. I am also personally excited to be working directly with Dr. Daniel Prince, who I consider a leading thinker in our field.”
 
Gibraltar will complement Sotera Health’s Nelson Labs business. Gibraltar’s expertise in pharmaceutical products and analytical testing capabilities will enhance Nelson Labs’ existing strengths in medical device microbiology and expert advisory services. Gibraltar’s facilities are FDA registered and ISO 17025 accredited and have the distinction of being accredited for both the microbiological and chemical fields. The acquisition of Gibraltar Laboratories does not include Prince Sterilization Services, LLC. However, both companies are excited that Gibraltar will continue to maintain a partnership with Prince Sterilization Services to provide the testing needed to certify their products.